Insulin-like growth factor I (IGF I) is structurally similar to insulin and shares many of its biologic properties. We compared the short-term metabolic effects of recombinant IGF I (100 micrograms [13.3 nmol] per kilogram of body weight) and insulin (0.15 IU [1 nmol] per kilogram) in eight healthy volunteers (four men and four women). The hypoglycemic responses to both hormones were nearly identical in the doses used. The lowest blood glucose levels were reached after 30 minutes: 1.98 +/- 0.44 mmol per liter after IGF I and 1.78 +/- 0.29 after insulin. On a molar basis, IGF I was only 6 percent as potent as insulin in the production of hypoglycemia. Insulin also inhibited lipolysis more effectively than IGF I. Levels of epinephrine, norepinephrine, growth hormone, glucagon, and cortisol responded similarly to both agents. The hypoglycemia produced by IGF I is probably due to the supraphysiologic concentrations of the free peptide that result from its rapid intravenous injection. Fifteen minutes after injection, the serum level of IGF I increased from 144 +/- 38 ng per milliliter at base line to 424 +/- 56, of which 80 percent was free in the plasma (not bound to IGF carrier proteins). The determination of whether any of the short-term metabolic effects of IGF I have any clinical application will require further investigation.
This article has been cited by other articles:
Fu, Q., Yu, X., Callaway, C. W., Lane, R. H., McKnight, R. A.
(2009). Epigenetics: intrauterine growth retardation (IUGR) modifies the histone code along the rat hepatic IGF-1 gene. FASEB J.
23: 2438-2449
[Abstract][Full Text]
Holland-Fischer, P., Vilstrup, H., Frystyk, J., Nielsen, D. T., Flyvbjerg, A., Gronbaek, H.
(2009). The IGF system after insertion of a transjugular intrahepatic porto-systemic shunt in patients with liver cirrhosis. Eur J Endocrinol
160: 957-963
[Abstract][Full Text]
Lacy, M. Q., Alsina, M., Fonseca, R., Paccagnella, M. L., Melvin, C. L., Yin, D., Sharma, A., Enriquez Sarano, M., Pollak, M., Jagannath, S., Richardson, P., Gualberto, A.
(2008). Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma. JCO
26: 3196-3203
[Abstract][Full Text]
Collett-Solberg, P. F., Misra, M., on behalf of the Drug and Therapeutics Committee o,
(2008). The Role of Recombinant Human Insulin-Like Growth Factor-I in Treating Children with Short Stature. J. Clin. Endocrinol. Metab.
93: 10-18
[Abstract][Full Text]
Ryan, P. D., Goss, P. E.
(2008). The Emerging Role of the Insulin-Like Growth Factor Pathway as a Therapeutic Target in Cancer. The Oncologist
13: 16-24
[Abstract][Full Text]
Kaplan, S. A., Cohen, P.
(2007). REVIEW: The Somatomedin Hypothesis 2007: 50 Years Later. J. Clin. Endocrinol. Metab.
92: 4529-4535
[Abstract][Full Text]
Haluska, P., Shaw, H. M., Batzel, G. N., Yin, D., Molina, J. R., Molife, L. R., Yap, T. A., Roberts, M. L., Sharma, A., Gualberto, A., Adjei, A. A., de Bono, J. S.
(2007). Phase I Dose Escalation Study of the Anti Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors. Clin. Cancer Res.
13: 5834-5840
[Abstract][Full Text]
Ekstrom, K., Salemyr, J., Zachrisson, I., Carlsson-Skwirut, C., Ortqvist, E., Bang, P.
(2007). Normalization of the IGF-IGFBP Axis by Sustained Nightly Insulinization in Type 1 Diabetes. Diabetes Care
30: 1357-1363
[Abstract][Full Text]
Li, X., Madison, B. B., Zacharias, W., Kolterud, A., States, D., Gumucio, D. L.
(2007). Deconvoluting the intestine: molecular evidence for a major role of the mesenchyme in the modulation of signaling cross talk. Physiol. Genomics
29: 290-301
[Abstract][Full Text]
Ning, Y., Schuller, A. G. P., Bradshaw, S., Rotwein, P., Ludwig, T., Frystyk, J., Pintar, J. E.
(2006). Diminished Growth and Enhanced Glucose Metabolism in Triple Knockout Mice Containing Mutations of Insulin-Like Growth Factor Binding Protein-3, -4, and -5. Mol. Endocrinol.
20: 2173-2186
[Abstract][Full Text]
Leray, V., Siliart, B., Dumon, H., Martin, L., Sergheraert, R., Biourge, V., Nguyen, P.
(2006). Protein Intake Does Not Affect Insulin Sensitivity in Normal Weight Cats. J. Nutr.
136: 2028S-2030S
[Full Text]
Pennisi, P., Gavrilova, O., Setser-Portas, J., Jou, W., Santopietro, S., Clemmons, D., Yakar, S., LeRoith, D.
(2006). Recombinant Human Insulin-Like Growth Factor-I Treatment Inhibits Gluconeogenesis in a Transgenic Mouse Model of Type 2 Diabetes Mellitus. Endocrinology
147: 2619-2630
[Abstract][Full Text]
Camacho-Hubner, C., Rose, S., Preece, M. A., Sleevi, M., Storr, H. L., Miraki-Moud, F., Minuto, F., Frystyk, J., Rogol, A., Allan, G., Sommer, A., Savage, M. O.
(2006). Pharmacokinetic Studies of Recombinant Human Insulin-Like Growth Factor I (rhIGF-I)/rhIGF-Binding Protein-3 Complex Administered to Patients with Growth Hormone Insensitivity Syndrome. J. Clin. Endocrinol. Metab.
91: 1246-1253
[Abstract][Full Text]
Li, J., Stenbog, E., Bush, A., Grofte, T., Redington, A. N., Penny, D. J.
(2004). Insulin-like growth factor 1 improves the relationship between systemic oxygen consumption and delivery in piglets after cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg.
127: 1436-1441
[Abstract][Full Text]
Simpson, H. L., Jackson, N. C., Shojaee-Moradie, F., Jones, R. H., Russell-Jones, D. L., Sonksen, P. H., Dunger, D. B., Umpleby, A. M.
(2004). Insulin-Like Growth Factor I Has a Direct Effect on Glucose and Protein Metabolism, But No Effect on Lipid Metabolism in Type 1 Diabetes. J. Clin. Endocrinol. Metab.
89: 425-432
[Abstract][Full Text]
Wan, Y.-J. Y., Han, G., Cai, Y., Dai, T., Konishi, T., Leng, A.-S.
(2003). Hepatocyte Retinoid X Receptor-{alpha}-Deficient Mice Have Reduced Food Intake, Increased Body Weight, and Improved Glucose Tolerance. Endocrinology
144: 605-611
[Abstract][Full Text]
Norby, F. L., Wold, L. E., Duan, J., Hintz, K. K., Ren, J.
(2002). IGF-I attenuates diabetes-induced cardiac contractile dysfunction in ventricular myocytes. Am. J. Physiol. Endocrinol. Metab.
283: E658-E666
[Abstract][Full Text]
Pratipanawatr, T., Pratipanawatr, W., Rosen, C., Berria, R., Bajaj, M., Cusi, K., Mandarino, L., Kashyap, S., Belfort, R., DeFronzo, R. A.
(2002). Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. Am. J. Physiol. Endocrinol. Metab.
282: E1360-E1368
[Abstract][Full Text]
Firth, S. M., MCDougall, F., MCLachlan, A. J., Baxter, R. C.
(2002). Impaired Blockade of Insulin-Like Growth Factor I (IGF-I)-Induced Hypoglycemia by IGF Binding Protein-3 Analog with Reduced Ternary Complex-Forming Ability. Endocrinology
143: 1669-1676
[Abstract][Full Text]
Laron, Z
(2001). Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol. Pathol.
54: 311-316
[Abstract][Full Text]
Anker, S. D., Volterrani, M., Pflaum, C.-D., Strasburger, C. J., Osterziel, K. J., Doehner, W., Ranke, M. B., Poole-Wilson, P. A., Giustina, A., Dietz, R., Coats, A. J. S.
(2001). Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol
38: 443-452
[Abstract][Full Text]
Sjogren, K., Wallenius, K., Liu, J.-L., Bohlooly-Y, M., Pacini, G., Svensson, L., Tornell, J., Isaksson, O. G.P., Ahren, B., Jansson, J.-O., Ohlsson, C.
(2001). Liver-Derived IGF-I is of Importance for Normal Carbohydrate and Lipid Metabolism. Diabetes
50: 1539-1545
[Abstract][Full Text]
Hayes, V. Y., Urban, R. J., Jiang, J., Marcell, T. J., Helgeson, K., Mauras, N.
(2001). Recombinant Human Growth Hormone and Recombinant Human Insulin-Like Growth Factor I Diminish the Catabolic Effects of Hypogonadism in Man: Metabolic and Molecular Effects. J. Clin. Endocrinol. Metab.
86: 2211-2219
[Abstract][Full Text]
Friedlander, A. L., Butterfield, G. E., Moynihan, S., Grillo, J., Pollack, M., Holloway, L., Friedman, L., Yesavage, J., Matthias, D., Lee, S., Marcus, R., Hoffman, A. R.
(2001). One Year of Insulin-Like Growth Factor I Treatment Does Not Affect Bone Density, Body Composition, or Psychological Measures in Postmenopausal Women. J. Clin. Endocrinol. Metab.
86: 1496-1503
[Abstract][Full Text]
Le Roith, D., Bondy, C., Yakar, S., Liu, J.-L., Butler, A.
(2001). The Somatomedin Hypothesis: 2001. Endocr. Rev.
22: 53-74
[Abstract][Full Text]
Gianotti, L., Maccario, M., Lanfranco, F., Ramunni, J., Di Vito, L., Grottoli, S., Muller, E. E., Ghigo, E., Arvat, E.
(2000). Arginine Counteracts the Inhibitory Effect of Recombinant Human Insulin-Like Growth Factor I on the Somatotroph Responsiveness to Growth Hormone-Releasing Hormone in Humans. J. Clin. Endocrinol. Metab.
85: 3604-3608
[Abstract][Full Text]
Mauras, N., Martinez, V., Rini, A., Guevara-Aguirre, J.
(2000). Recombinant Human Insulin-Like Growth Factor I Has Significant Anabolic Effects in Adults with Growth Hormone Receptor Deficiency: Studies on Protein, Glucose, and Lipid Metabolism. J. Clin. Endocrinol. Metab.
85: 3036-3042
[Abstract][Full Text]
Cusi, K., DeFronzo, R.
(2000). Recombinant Human Insulin-Like Growth Factor I Treatment for 1 Week Improves Metabolic Control in Type 2 Diabetes by Ameliorating Hepatic and Muscle Insulin Resistance. J. Clin. Endocrinol. Metab.
85: 3077-3084
[Abstract][Full Text]
Clemmons, D. R., Moses, A. C., McKay, M. J., Sommer, A., Rosen, D. M., Ruckle, J.
(2000). The Combination of Insulin-Like Growth Factor I and Insulin-Like Growth Factor-Binding Protein-3 Reduces Insulin Requirements in Insulin-Dependent Type 1 Diabetes: Evidence for in VivoBiological Activity. J. Clin. Endocrinol. Metab.
85: 1518-1524
[Abstract][Full Text]
Mauras, N., O’Brien, K. O., Welch, S., Rini, A., Helgeson, K., Vieira, N. E., Yergey, A. L.
(2000). Insulin-Like Growth Factor I and Growth Hormone (GH) Treatment in GH-Deficient Humans: Differential Effects on Protein, Glucose, Lipid, and Calcium Metabolism. J. Clin. Endocrinol. Metab.
85: 1686-1694
[Abstract][Full Text]
Frick, F., Oscarsson, J., Vikman-Adolfsson, K., Ottosson, M., Yoshida, N., Eden, S.
(2000). Different effects of IGF-I on insulin-stimulated glucose uptake in adipose tissue and skeletal muscle. Am. J. Physiol. Endocrinol. Metab.
278: E729-E737
[Abstract][Full Text]
LeRoith, D.
(1999). Insulin-like Growth Factors in Pediatric Health and Disease. J. Clin. Endocrinol. Metab.
84: 4355-4361
[Full Text]
(1999). The Essential Role of IGF-I: Lessons from the Long-Term Study and Treatment of Children and Adults with Laron Syndrome. J. Clin. Endocrinol. Metab.
84: 4397-4404
[Abstract][Full Text]
Mauras, N., Quarmby, V., Bloedow, D. C.
(1999). Pharmacokinetics of insulin-like growth factor I in hypopituitarism: correlation with binding proteins. Am. J. Physiol. Endocrinol. Metab.
277: E579-E584
[Abstract][Full Text]
Levitt Katz, L. E., Ferry, R. J. Jr., Stanley, C. A., Collett-Solberg, P. F., Baker, L., Cohen, P.
(1999). Suppression of Insulin Oversecretion by Subcutaneous Recombinant Human Insulin-Like Growth Factor I in Children with Congenital Hyperinsulinism Due to Defective {beta}-Cell Sulfonylurea Receptor. J. Clin. Endocrinol. Metab.
84: 3117-3124
[Abstract][Full Text]
Ghigo, E., Gianotti, L., Arvat, E., Ramunni, J., Valetto, M. R., Broglio, F., Rolla, M., Cavagnini, F., Müller, E. E.
(1999). Effects of Recombinant Human Insulin-Like Growth Factor I Administration on Growth Hormone (GH) Secretion, Both Spontaneous and Stimulated by GH-Releasing Hormone or Hexarelin, a Peptidyl GH Secretagogue, in Humans. J. Clin. Endocrinol. Metab.
84: 285-290
[Abstract][Full Text]
Dominguez, L. J., Barbagallo, M., Sowers, J. R., Resnick, L. M.
(1998). Magnesium Responsiveness to Insulin and Insulin-Like Growth Factor I in Erythrocytes from Normotensive and Hypertensive Subjects. J. Clin. Endocrinol. Metab.
83: 4402-4407
[Abstract][Full Text]
Chapman, I. M., Hartman, M. L., Pieper, K. S., Skiles, E. H., Pezzoli, S. S., Hintz, R. L., Thorner, M. O.
(1998). Recovery of Growth Hormone Release from Suppression by Exogenous Insulin-Like Growth Factor I (IGF-I): Evidence for a Suppressive Action of Free Rather Than Bound IGF-I. J. Clin. Endocrinol. Metab.
83: 2836-2842
[Abstract][Full Text]
Rajaram, S., Baylink, D. J., Mohan, S.
(1997). Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions. Endocr. Rev.
18: 801-831
[Abstract][Full Text]
Chapman, I. M., Hartman, M. L., Pezzoli, S. S., Harrell, F. E. Jr., Hintz, R. L., Alberti, K. G. M. M., Thorner, M. O.
(1997). Effect of Aging on the Sensitivity of Growth Hormone Secretion to Insulin-Like Growth Factor-I Negative Feedback. J. Clin. Endocrinol. Metab.
82: 2996-3004
[Abstract][Full Text]
Frystyk, J., Grofte, T., Skjarbak, C., Orskov, H.
(1997). The Effect of Oral Glucose on Serum Free Insulin-Like Growth Factor-I and -II in Healthy Adults. J. Clin. Endocrinol. Metab.
82: 3124-3127
[Abstract][Full Text]
Berneis, K., Ninnis, R., Girard, J., Frey, B. M., Keller, U.
(1997). Effects of Insulin-Like Growth Factor I Combined with Growth Hormone on Glucocorticoid-Induced Whole-Body Protein Catabolism in Man. J. Clin. Endocrinol. Metab.
82: 2528-2534
[Abstract][Full Text]
Nyomba, B. L. G., Berard, L., Murphy, L. J.
(1997). Free Insulin-Like Growth Factor I (IGF-I) in Healthy Subjects: Relationship with IGF-Binding Proteins and Insulin Sensitivity. J. Clin. Endocrinol. Metab.
82: 2177-2181
[Abstract][Full Text]
Kopple, J. D.
(1996). 1995 Jonathan E. Rhoads Lecture. The Nutrition Management of the Patient With Acute Renal Failure. JPEN J Parenter Enteral Nutr
20: 3-12
[Abstract]
Ziegler, T. R., Young, L. S., Ferrari-Baliviera, E., Demling, R. H., Wilmore, D. W.
(1990). Use of Human Growth Hormone Combined with Nutritional Support in a Critical Care Unit. JPEN J Parenter Enteral Nutr
14: 574-581
[Abstract]
Roth, R.
(1988). Structure of the receptor for insulin-like growth factor II: the puzzle amplified. Science
239: 1269-1271
[Abstract]
Previous
